Preventing treatment delays for benign gynaecological conditions

Other OA: gold CC0
⚙ AI-generated summary by qwen3.7-flash+body, 2026-10-11 ⓘ

This paper reviews innovative strategies, including remote consultations and ambulatory services, to address the dramatic rise in surgical waiting lists for benign gynaecological conditions resulting from pandemic-related management delays.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-10-11 · read from full text ⓘ

This paper examines the significant delays in managing benign gynaecological conditions within the English National Health Service, highlighting a dramatic rise in surgical waiting lists following the pandemic. It reviews innovative strategies to address this backlog, including the expansion of remote consultations, primary care management guidelines, and ambulatory outpatient services for procedures like hysteroscopy. The text also discusses systemic initiatives such as the Getting It Right First Time programme aimed at improving productivity through data-driven benchmarking and shifting low-complexity surgeries to specialized centers. Relevance to endometriosis: listed among benign gynaecological conditions requiring surgical management, though the paper's main focus is on general service delivery and waiting list reduction rather than specific disease pathology or treatment protocols for endometriosis or adenomyosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 4,716 characters · extracted from pmc-nxml · 5 sections · click to expand

The

Whilst the management of gynaecological oncology patients and care for gynaecological emergencies continued throughout the pandemic, there was considerable delay in the management of benign gynaecological conditions and we have now seen a dramatic rise in the waiting lists for surgery. Within England the waiting times for gynaecological operations continues to grow and as of June 2022 there were 540,488 patients waiting, with 34,317 patients waiting for over 52 weeks. In addition, the waiting list continues to grow by 9383 cases per month [ 1 ]. In a public health system, such as the National Health Service (NHS), with limited resources this represents a significant challenge which innovative ways of providing healthcare are hoping to solve.

Inpatient

Perhaps one of the greatest challenges currently facing many healthcare systems is how to address the significant backlog in inpatient benign gynaecological cases which has accrued during the pandemic. Novel solutions have included moving NHS cases into the private medical sector as well as extending lists into the evening and weekends. However, even with this added capacity surgical waiting lists continue to increase in length and innovative solutions continue to be introduced. Getting It Right First Time (GIRFT) is a national programme [ 7 ] designed to improve the treatment and care of patients through in-depth review of services, benchmarking and using data-driven evidence to support change. Initially trialled in orthopaedic surgery, GIRFT is now being introduced nationwide in gynaecology to try to improve productivity and reduce waiting lists [ 8 ]. One of the key recommendations from this report is to focus low-complexity high-volume surgery, such as diagnostic procedures, in surgical centres which are often remote from the main hospital and by doing so reducing the need for inpatient capacity.

Conclusion

The provision of timely and responsive healthcare for benign gynaecological conditions has always been challenging as many specialities take precedence in terms of funding and capacity. Emerging from the effects of the pandemic we have seen an unprecedented rise in surgical workload and many women are now waiting for a substantial time before treatment. Clearly this has an important implication in terms of health-related quality of life (HRQoL) and well-being. Novel and innovative solutions are now central in trying to improve patient access to care and whilst this may initially seem to be a challenge, ultimately it may prove to be an opportunity to reappraise how we develop and deliver healthcare.

Management

Throughout the pandemic, telephone and video consultations became widespread and there has been a permanent change in the way that consultations are delivered in primary care, and many practices are still limiting face-to-face contact. Pre-pandemic evidence has suggested that telephone triage leads to a 20% increase in total general practice consultations with no change in the number of outpatient referrals and out-of-hours attendances [ 2 ] whilst the use of physician associates has also been shown to be an effective and safe use of resources [ 3 ]. Despite unfavourable comments within the media, the evidence would also appear to suggest that remote consultations are generally regarded positively and increase patient convenience [ 4 ]. Guidelines from the Royal College of Obstetricians and Gynaecologists (RCOG) have now been published to help facilitate primary care management [ 5 ] and the British Society of Urogynaecologists (BSUG) has also published guidelines covering the management of urogynaecological conditions and the management of vaginal pessaries [ 6 ].

Outpatient

Whilst many benign gynaecological conditions may be managed effectively in primary care there are still considerable pressures on outpatient services. One-stop clinics with integrated scanning facilities are being introduced to help streamline service provision and reduce the need for follow-up appointments. For those patients requiring further investigations there has been a rapid expansion of ambulatory services under local anaesthesia, including the use of outpatient hysteroscopy and cystoscopy. These include both diagnostic and operative hysteroscopic procedures such as resection of endometrial polyps and small submucous fibroids, as well as urogynaecological procedures such as intravesical administration of botulinum toxin for refractory detrusor overactivity and urethral bulking agents for the treatment of stress urinary incontinence. Development of an ambulatory outpatient service reduces the need for day case admissions and many procedures are now performed by nurse specialists, resulting is significant savings in time and cost.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: pmc-nxml ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (4)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:36:45.364535+00:00
License: CC0 · commercial use OK